Sleep apnea and excess weight feed each other, and for the first time there’s a weight loss drug approved to treat the breathing disorder itself. Zepbound (tirzepatide) is FDA-approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, based on trial data showing it substantially reduced apnea events. Other GLP-1 drugs like Wegovy (semaglutide) can help indirectly by driving the weight loss that eases OSA, though they aren’t specifically approved for it. Here’s how these options work and compare.<\/p>\n
In obstructive sleep apnea, the airway repeatedly narrows or collapses during sleep, briefly cutting off breathing dozens of times an hour. Excess weight is a leading cause because fat around the neck and upper airway crowds the space, and abdominal fat can reduce lung volume and make the airway less stable at night.<\/p>\n
The severity is measured by the apnea-hypopnea index (AHI), the number of breathing interruptions per hour. Untreated OSA is more than an inconvenience: it’s linked to high blood pressure, heart disease, and daytime exhaustion. Because weight is such a strong driver, losing a significant amount often lowers AHI, which is precisely where these medications come in.<\/p>\n
Tirzepatide earned its OSA approval on the strength of a dedicated trial program. In the SURMOUNT-OSA trials<\/a> published in the New England Journal of Medicine in 2024, adults with moderate-to-severe OSA and obesity who took tirzepatide had large reductions in apnea events, along with lower body weight, blood pressure, and inflammation, whether or not they also used a CPAP machine. For many participants the improvement was enough to meaningfully change their disease severity.<\/p>\n That result is why tirzepatide (sold as Zepbound for weight-related uses) became the first medication cleared specifically for OSA in adults with obesity, rather than just for weight loss that happens to help.<\/p>\n TrimRx prescribes compounded tirzepatide and brand Zepbound, as well as semaglutide options, so the medication with the strongest OSA evidence is available after a provider review. CPAP remains a mainstay and pairs well with weight loss rather than competing with it. Importantly, medication and CPAP are not mutually exclusive; the trial benefits held in people using CPAP too.<\/p>\n Consider a hypothetical patient with a BMI of 36 and moderate OSA who finds CPAP hard to tolerate every night. A GLP-1 that lowers his weight could reduce his apnea severity over time, potentially making his nights more manageable, though he would keep working with his sleep provider to monitor progress with a repeat sleep study.<\/p>\nComparing the Options<\/h3>\n
\n\n
\n \nOption<\/th>\n How it works<\/th>\n OSA status<\/th>\n Notes<\/th>\n<\/tr>\n<\/thead>\n \n Tirzepatide (Zepbound)<\/td>\n Weekly injection, up to ~21% weight loss<\/td>\n FDA-approved for moderate-to-severe OSA with obesity<\/td>\n Direct trial evidence of reduced apnea events<\/td>\n<\/tr>\n \n Semaglutide (Wegovy)<\/td>\n Weekly injection, ~15% weight loss<\/td>\n Not specifically approved for OSA<\/td>\n Helps indirectly via weight loss<\/td>\n<\/tr>\n \n CPAP therapy<\/td>\n Keeps airway open with air pressure<\/td>\n Standard first-line device<\/td>\n Treats symptoms nightly, doesn’t address weight<\/td>\n<\/tr>\n \n Combined approach<\/td>\n Medication plus CPAP<\/td>\n Common in practice<\/td>\n Weight loss may reduce reliance on the device over time<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n